Table 4 Association between TMPRSS2 polymorphism with mortality/survival in patients with moderate-severe COVID-19
From: Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients
| Â | Moderate COVID-19 (N=32) | Severe COVID-19 (N=30) | ||
|---|---|---|---|---|
| Â | Recovered (N=29, 90.6%) | Died (N=3, 9.4%) | Recovered (N=12, 30%) | Died (N=18, 60%) |
Genotype (amino acids) | ||||
 CC (Val/Val) | 16 (50%) | 1 (3.1%) | 3 (10 %) | 10 (33.3%) |
 CT (Val/Met) | 10 (31.3%) | 1 (3.1%) | 4 (13.3%) | 6 (20 %) |
 TT (Met/Met) | 3 (9.4%) | 1 (3.1%) | 5 (16.7%) | 2 (6.7%) |
| Â | Chi-square test P=0.498 | Chi-square test P=0.109 | ||
| Â | Linear-by-linear chi-square association test P=0.299 | Linear-by-linear chi-square association test P=0.042 | ||